Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

Wed, 26 Mar 2025 06:50:00 EST

Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025

NEWARK, N.J. and GAINESVILLE,...

Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)

Fri, 07 Feb 2025 08:05:00 EST

First data in NPC1 on treatment in this age group over a period of 48 weeks

At 24 weeks of the sub-study, 7 of 8 patients (87%) and at 48 weeks of the sub-study, 6 of 7 patients (86%) show stabilization or improvement in Clinical Global Impression - Change (CGI-C) Scale

Data presented at the 21^st Annual WORLDSymposium™ 2025

Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025

Tue, 14 Jan 2025 08:05:00 EST

Pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol^® Cyclo™ for Niemann-Pick Disease Type C1 ("NPC1") to be highlighted in an oral presentation

GAINESVILLE, Fla. -

Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Thu, 14 Nov 2024 08:05:00 EST

Strategic merger with Rafael Holdings to combine two companies and advance Trappsol^® Cyclo™ for NPC1 patients expected to close Q4 2024

Company on track for topline data from the 48-week interim analysis of 104 enrolled patients in TransportNPC™ in H1 2025

Submission of New Drug Application (NDA) to the Food and Drug Administration (FDA) and...

Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Thu, 05 Sep 2024 09:05:00 EST

Two posters presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024
Pivotal TransportNPC™ study is the most comprehensive ongoing controlled pivotal study regarding patient size, global footprint, duration and clinical outcomes for NPC1
Topline data from the 48-week interim analysis of 104 enrolled patients in...

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

Thu, 22 Aug 2024 06:50:00 EST

Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol^® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025
NEWARK, N.J. & GAINESVILLE, Fla. - Rafael Holdings, Inc....

Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Thu, 15 Aug 2024 09:00:00 EST

Quarter marked by achievement of landmark milestone with completion of enrollment in pivotal Phase 3 study ("TransportNPC™") evaluating Trappsol^® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1)
Topline data from the 48-week interim analysis of 104 enrolled patients in TransportNPC™ on track for H1 2025

Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer's Disease from European Patent Office

Mon, 29 Jul 2024 09:05:00 EST

GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to...

Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024

Tue, 25 Jun 2024 09:25:00 EST

GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to...

Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1

Thu, 30 May 2024 09:00:00 EST

TransportNPC™ is the most comprehensive ongoing controlled pivotal study regarding patient size, global footprint, duration and clinical outcomes for the treatment of Niemann-Pick Disease Type C1 (NPC1)
Topline data from the 48-week interim analysis of 104 enrolled patients is anticipated for H1 2025
If 48-week data demonstrate significance, submission of New...

Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Thu, 16 May 2024 08:05:00 EST

Ongoing progress toward last patient enrolled in pivotal Phase 3 study ("TransportNPC™") evaluating Trappsol^® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1), expected Q2 2024
Topline data from 48-week interim analysis expected H1 2025
GAINESVILLE, Fla. -

Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Mon, 18 Mar 2024 09:05:00 EST

Continued progress of pivotal Phase 3 study (TransportNPC™) evaluating Trappsol^®Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) toward 48-week comparative interim analysis data readout, planned for Q1 2025
Aligned development strategy for Trappsol^®Cyclo™ with FDA to enable a patient population lacking available therapies to have...

Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer's Disease

Thu, 14 Mar 2024 09:34:00 EST

GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to...

Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease from the U.S. Patent and Trademark Office

Mon, 29 Jan 2024 09:15:00 EST

GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to...

Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.

Wed, 27 Dec 2023 16:15:00 EST

Combined company operating as Cyclo Therapeutics with primary focus on advancing Trappsol^® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1)
Cash runway extended into 2H 2024 with approximately $11.0 million cash on hand to fund operations
GAINESVILLE, Fla. -

Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1

Mon, 18 Dec 2023 09:15:00 EST

Ongoing pivotal Phase 3 study ("TransportNPC™") evaluating Trappsol^® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1)
FDA feedback provides direction for the comparative interim analysis
With aligned strategy, interim analysis data readout is anticipated for Q1 2025
FDA and Cyclo Therapeutics...

Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024

Tue, 21 Nov 2023 08:05:00 EST

Pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol^®Cyclo™ for Niemann-Pick Disease Type C1 ("NPC1") to be highlighted in a platform presentation
GAINESVILLE, Fla. -

Cyclo Therapeutics Reports Third Quarter 2023 Financial Results

Wed, 15 Nov 2023 08:05:00 EST

Strong pace of enrollment continues in pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol^®Cyclo™ for Niemann-Pick Disease Type C1 ("NPC1")
Merger with Applied Molecular Transport, Inc. ("AMT") on track to close before year end
Company continues to bolster cash position to extend runway through clinical and regulatory...

Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million

Mon, 23 Oct 2023 08:05:00 EST

Issues New Warrants to this Investment Group for Possible Additional Funding of Up to $3.47 Million (if exercised)
GAINESVILLE, Fla. -

Cyclo Therapeutics to Present at 8th Annual Dawson James Conference

Thu, 05 Oct 2023 08:05:00 EST

Live webcast presentation on Thursday, October 12^th at 12:00 PM ET
GAINESVILLE, Fla. -

Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement

Thu, 21 Sep 2023 08:05:00 EST

Combined company will operate as Cyclo Therapeutics with primary focus on advancing Trappsol^® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1)
At closing combined Company will have approximately $13.7 million cash on hand to fund operations into 2H 2024
Upcoming milestones include completion of enrollment in pivotal Phase 3 clinical...

Cyclo Therapeutics Reports Second Quarter 2023 Financial Results

Tue, 15 Aug 2023 08:05:00 EST

Continued strong enrollment of pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol^®Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) on track to complete enrollment by year end 2023
Company anticipates achieving 60% of enrollment of TransportNPC™ by end of August
Topline results from TransportNPC™ expected Q4...

Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

Wed, 02 Aug 2023 08:16:00 EST

GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to...

Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1

Thu, 29 Jun 2023 13:32:00 EST

- Data published in official journal of Molecular Genetics and Metabolism Reports:

Evidence of a change in cholesterol homeostasis in peripheral organs and the brain after the initial infusion

Trappsol^® Cyclo™ was detected in the CSF

Completers had an 88.9% improvement in at least two domains of the 17-Domain Niemann-Pick Type C1 Clinical...

Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol® Cyclo™ for Alzheimer's Disease

Mon, 12 Jun 2023 08:05:00 EST

GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to...

Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement

Mon, 05 Jun 2023 08:05:00 EST

GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to...

Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

Mon, 15 May 2023 08:05:00 EST

Company on track to complete enrollment in ongoing pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol^® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) by year end 2023

GAINESVILLE, Fla. -

Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)

Tue, 02 May 2023 08:12:00 EST

GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to...

Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Fri, 21 Apr 2023 08:05:00 EST

GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to...

Cyclo Therapeutics Provides Business Update and Reports Full Year 2022 Financial Results

Mon, 20 Mar 2023 08:05:00 EST

Pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol^® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) projected 40% enrolled by the end of March; Company on track to complete enrollment by year end 2023

Phase 2b study of Trappsol^® Cyclo™ for the treatment of early Alzheimer's Disease (AD) enrollment and dosing...

Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements

Wed, 11 Jan 2023 08:05:00 EST

Continued progress in ongoing pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol^® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) with 35% of expected enrollment completed, on track to complete enrollment by year end 2023

Patient enrollment and dosing in Phase 2b study of Trappsol^® Cyclo™ for the treatment of early...

Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event

Tue, 10 Jan 2023 08:05:00 EST

Live video webcast on Thursday, January 19^th at 11:00 AM ET
GAINESVILLE, Fla. -

Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer's Disease

Mon, 09 Jan 2023 08:05:00 EST

- Biologic similarities demonstrated between Niemann-Pick Disease Type C and Alzheimer's disease, including cholesterol accumulation in regions of the brain, elevated levels of Tau in CSF, and amyloid plaques in the brain, bolsters rationale for studying Trappsol^® Cyclo™ for the treatment of early Alzheimer's disease
GAINESVILLE, Fla....

Cyclo Therapeutics Announces Closing of $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Wed, 04 Jan 2023 16:05:00 EST

GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the closing of its previously announced registered direct offering for the purchase and sale of 2,608,696 shares of common stock (or...

Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

Wed, 04 Jan 2023 08:05:00 EST

GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to...

Cyclo Therapeutics Announces $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Fri, 30 Dec 2022 08:00:00 EST

GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 2,608,696 shares of common stock (or...

Cyclo Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Achievements

Fri, 11 Nov 2022 08:05:00 EST

- Quarter marked by launch of Phase 2b study of Trappsol^® Cyclo™ for the treatment of early Alzheimer's Disease (AD) with patient enrollment and site activation now underway
- Building momentum with ongoing advancement of global pivotal study (TransportNPC™) evaluating Trappsol^® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1)

Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Tue, 18 Oct 2022 08:05:00 EST

- Data published in official journal of the Society for Inherited Metabolic Disorders, Molecular Genetics and Metabolism
- Published trial data show that Trappsol^® Cyclo™ overcomes the NPC1 defect by removing trapped cholesterol from cells both systemically and in the central nervous system (CNS)
- Company advancing ongoing global pivotal Phase 3...

Cyclo Therapeutics Commences Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer's Disease

Tue, 04 Oct 2022 08:05:00 EST

Patient enrollment and site activation now underway
GAINESVILLE, Fla. - Cyclo...

Cyclo Therapeutics Provides Business Update

Wed, 28 Sep 2022 14:02:00 EST

- Company on track to commence enrollment and dosing of Phase 2 study of Trappsol^® Cyclo™ for the treatment of Alzheimer's disease before year end
- Ongoing advancement of global pivotal study (TransportNPC™) evaluating Trappsol^® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1)
- Company to participate at the 2022 NPUK...

Cyclo Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Wed, 07 Sep 2022 08:05:00 EST

GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to...

Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

Tue, 16 Aug 2022 08:05:00 EST

- On track to commence Phase 2 study of Trappsol^® Cyclo™ for the treatment of Alzheimer's Disease before year end
- Continued execution on advancement of lead development program evaluating Trappsol^® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) in ongoing global pivotal study (TransportNPC™)

Cyclo Therapeutics to Present at the China NPC Association Meeting

Mon, 08 Aug 2022 08:05:00 EST

GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to...

Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022

Thu, 21 Jul 2022 08:05:00 EST

GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to...

Cyclo Therapeutics to Present at the World Orphan Drug Congress USA 2022

Mon, 11 Jul 2022 08:05:00 EST

GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to...

Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation

Tue, 21 Jun 2022 08:05:00 EST

Presentation by Professor Caroline Hastings, MD, Chair of the Phase 3 Trappsol^® Cyclo™ Program Steering Committee and the Global Principal Investigator for the Company's ongoing TransportNPC™ study evaluating Trappsol^® Cyclo™ for the treatment of Niemann-Pick Disease Type C (NPC)
GAINESVILLE, Fla. -...

Cyclo Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

Wed, 18 May 2022 08:00:00 EST

GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a late clinical stage biotechnology company dedicated to...

Cyclo Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

Thu, 12 May 2022 16:05:00 EST

- Continued advancement of lead development program evaluating Trappsol^® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) in ongoing global pivotal study (TransportNPC™)
- Phase 2 study of Trappsol^® Cyclo™ for the treatment of Alzheimer's Disease on track to commence patient enrollment this year
- Research collaboration...

Cyclo Therapeutics to Participate in the Virtual Investor Niemann-Pick Disease Type C Spotlight Event

Mon, 09 May 2022 08:05:00 EST

- Live video webcast with moderated fireside chat with members of the Cyclo Therapeutics leadership team and Global Principal Investigator for the Phase 3 study, Professor Caroline Hastings, MD, on Monday, May 16^th at 2:00 PM ET
GAINESVILLE, Fla. -

Cyclo Therapeutics News powered by B2i Technologies - SmartWire

Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)

Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025

Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer's Disease from European Patent Office

Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024

Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1

Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer's Disease

Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease from the U.S. Patent and Trademark Office

Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.

Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1

Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024

Cyclo Therapeutics Reports Third Quarter 2023 Financial Results

Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million

Cyclo Therapeutics to Present at 8th Annual Dawson James Conference

Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement

Cyclo Therapeutics Reports Second Quarter 2023 Financial Results

Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1

Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol® Cyclo™ for Alzheimer's Disease

Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement

Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)

Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Cyclo Therapeutics Provides Business Update and Reports Full Year 2022 Financial Results

Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements

Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event

Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer's Disease

Cyclo Therapeutics Announces Closing of $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

Cyclo Therapeutics Announces $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Cyclo Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Achievements

Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Cyclo Therapeutics Commences Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer's Disease

Cyclo Therapeutics Provides Business Update

Cyclo Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

Cyclo Therapeutics to Present at the China NPC Association Meeting

Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022

Cyclo Therapeutics to Present at the World Orphan Drug Congress USA 2022

Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation

Cyclo Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

Cyclo Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

Cyclo Therapeutics to Participate in the Virtual Investor Niemann-Pick Disease Type C Spotlight Event